GHW International

GHW International

HHKEX:9933
1.70
HKD
+0.02
(+0.89%)
1.27BMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.61
2.18
2.15
1.97
2.13
2.83
3.38
3.3
4.09
4.36
- -
Basic EPS, GAAP
0.02
0.08
0.07
0.03
-0.01
0.13
0.27
- -
0.01
0.01
- -
Free Cash Flow per Basic Share
0.02
0.01
-0.02
-0.07
-0.22
-0.34
-0.05
-0.02
-0.1
0.1
- -
Dividend per Share
- -
0.01
0.01
0.05
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.06
0.09
0.09
0.11
0.21
0.34
0.6
0.58
0.62
0.63
0.67
Tangible Book Value per Share
0.04
0.07
0.06
0.11
0.2
0.34
0.59
0.58
0.61
0.62
0.66
Basic Weighted Avg Shares
1,000
1,000
1,000
1,000
986
1,000
1,000
975
944
944
945
Sales/Revenue/Turnover
1,607
2,179
2,153
1,966
2,104
2,833
3,379
3,218
3,862
4,113
- -
Operating Margin (%)
1.44
5.14
4.78
2.08
1.61
6.34
9.83
0.74
1.47
1.06
- -
Depreciation Expense
14
17
17
26
- -
9
12
14
- -
- -
- -
Net Income, GAAP
19
78
74
29
-5
131
275
3
13
13
- -
Effective Tax Rate (%)
2.14
15.55
18.62
8.6
- -
10.5
10.84
- -
- -
24.52
- -
Profit Margin (%)
1.19
3.59
3.45
1.48
-0.25
4.61
8.13
0.08
0.33
0.31
- -
Working Capital
-80
-80
-112
40
44
62
129
5
-128
-83
29
LT Debt
9
7
4
196
170
241
263
242
153
207
270
Total Equity
65
92
89
115
205
339
603
581
622
636
666
Return on Invested Capital (%)
- -
33.06
27.94
8.15
- -
17.03
24.78
- -
- -
2.16
- -
Return on Capital (%)
- -
34.73
29.74
9.69
- -
17.33
26.69
- -
- -
2.68
- -
Return on Common Equity (%)
- -
101.78
81.84
28.6
-3.23
48.01
58.33
0.46
2.19
2.15
- -

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
747
615
623
LT Borrowings
184
201
266
LT Finance Leases
5
6
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
945
944
943
Market Capitalization
1,311
1,527
1,102

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
1,160
1,121
1,232
Cash, Cash Equivalents & STI
156
116
137
Accounts Receivable, Net
270
297
275
Inventories
427
396
503
Total Current Liabilities
1,247
1,203
1,203
Payables & Accruals
- -
- -
- -
ST Debt
747
615
623
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
29.68%
2.27%
Free Cash Flow
- -
18.97%
-199.71%
Net Income, GAAP
- -
-449.38%
-0.28%
Sales/Revenue/Turnover
- -
15.14%
6.51%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
3,862
2025
- -
- -
4,113
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.01
2025
- -
- -
0.01
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Yanbin Yin
Full Time Employees
1,109
Sector
Process industries
Industry
Chemicals: specialty
Address
Building 06 Nanjing JS China
IPO Date
Jan 21, 2020
Business
GHW International is a global high-tech manufacturing enterprise headquartered in Nanjing, China, specializing in the research, development, production, and sales of applied chemicals, pharmaceutical intermediates, bio-based products, as well as sports and health products. Founded in 1995, the company operates through multiple business segments including Methylamine Industry Series, Applied Chemicals Series, Advanced Materials Intermediates Series, Green Products, Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (APIs), Iodine Derivatives and Supporting Products, and the Happy Elephant Planet Advanced Medical and Health Products segment. Its product portfolio encompasses animal nutrition chemical products such as choline chloride and betaine; polyurethane materials including polymer polyether and modified methylene diphenyl diisocyanate; fine chemical products; cardanol-based green products; pharmaceutical intermediates like cefpodoxime proxetil dispersible tablets; iodine derivatives; and a range of nutrition and health products sourced from third parties. The company serves customers across the People’s Republic of China, Southeast Asia, Europe, North America, and other international markets. In recent strategic developments, GHW International has expanded its footprint in health technology by entering into an exclusive distribution agreement with SWISSCOAT Vision (China) Limited to promote and sell customized medical optical lenses under the brand “瑞士寶” in China. The company continues to advance its strategy focused on green development, digital transformation, and globalization. It maintains comprehensive R&D capabilities, multiple production bases domestically and overseas, and an extensive warehousing and logistics system supporting over 40,000 clients worldwide. GHW also collaborates with governmental health authorities, exemplified by recent talks with Vietnam’s Ministry of Health to jointly explore pharmaceutical sector cooperation. GHW International’s operations span chemicals and pharmaceuticals industries, targeting markets in animal nutrition, construction, automotive, home appliances, coatings, and pharmaceuticals. The company maintains a global presence with subsidiaries in more than ten countries, supported by a supply chain of over 600 raw material suppliers. GHW emphasizes sustainable development, product quality, safety, and environmental protection as core principles underpinning its global manufacturing and sales activities. This comprehensive scope and recent strategic initiatives position GHW International as a diversified and integrated provider of chemical intermediates and advanced medical products with continued growth focus in health technology and international market expansion.